Rationale The indirect dopamine agonist methylphenidate remediates cognitive deficits in psychopathology, but the individual characteristics that determine its effects on the brain are not known. Objectives We aimed to determine whether targeted dopaminergically modulated traits and individual differences could predict neural response to methylphenidate across multiple functional magnetic resonance imaging (fMRI) procedures. Methods We combined neural measures from three separate procedures (two inhibitory control tasks differing in their degree of emotional salience and resting-state functional connectivity) during methylphenidate (20 mg oral, versus randomized and counterbalanced placebo) and correlated these aggregated responses with cocaine use disorder diagnosis (22 cocaine abusers, 21 controls), symptoms of attention deficit hyperactivity disorder, and working memory capacity. Results Cocaine abusers, relative to controls, had a lower response in the dorsolateral prefrontal cortex to methylphenidate across all three procedures, driven by responses to the two inhibitory control tasks; reduced methylphenidate fMRI response in this region further correlated with more frequent cocaine use. Conclusions Cocaine abuse (and its frequency), associated with lower tonic dopamine levels, correlated with a reduction in activation to methylphenidate (versus placebo). These initial results provide feasibility to the idea that multimodal fMRI tasks can be meaningfully aggregated, and that these aggregated procedures show a common disruption in addiction in a highly anticipated region relevant to cognitive control. Results also suggest that drug use frequency may represent an important modulatory variable in interpreting the efficacy of pharmacologically enhanced cognitive interventions in addiction.
Introduction
The mesocorticolimbic dopamine system is perturbed across many psychopathologies, including drug addiction and attention deficit hyperactivity disorder (ADHD), highlighting dopamine's role in supporting numerous functions that bear on these diseases [e.g., reward prediction (Schultz 2010) , incentive salience (Berridge 2007) , arousal (Horvitz 2000) , and novelty (Zald et al. 2008) ]. The Electronic supplementary material The online version of this article (doi:10.1007/s00213-016-4307-9) contains supplementary material, which is available to authorized users.
indirect dopamine and norepinephrine agonist methylphenidate (MPH) increases extracellular dopamine by blocking both transporters (Kuczenski and Segal 1997) and is thought to enhance attention and executive functioning by decreasing the energy requirements needed to perform cognitive tasks [i.e., by enhancing signal to noise ratio of neuronal activity (Swanson et al. 2011) and/or by modulating brain regions relevant to optimal task performance ]. Yet, the factors that predict an individual's response to MPH (e.g., as measured by modulation of activity in dopaminergic brain regions) are currently unknown. Uncovering the individual factors associated with MPH responsiveness, particularly when assessed across multiple functional magnetic resonance imaging (fMRI) tasks and procedures conducted in the same participants, could inform which individuals might benefit most from a pharmacologically enhanced cognitive intervention and, more broadly, can clarify if dopamine agonists exert consistent effects on brain function in health and disease across multiple contexts.
In the present study, we aggregated fMRI data collected during a MPH challenge targeting select dopaminergically innervated, anatomically defined cortical and subcortical brain regions of interest (ROIs) [orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), thalamus, hippocampus, midbrain, and striatum] across three different fMRI procedures: (a) a classical color-word Stroop task (Leung et al. 2000) ], (b) an emotional (drug) word variant of this Stroop task )], and (c) resting-state global functional connectivity density, which captures the overall number of functional connections to a given brain region . We then tested associations of responses in these regions with targeted, dopaminergically relevant individual difference variables that could predict an aggregated MPH-related response. Our primary interest was in (a) cocaine use disorder (CUD), as MPH modulated neural response (in ways suggesting a beneficial response) during tasks and during the resting state in prefrontal cortical regions (Goldstein et al. 2010; Li et al. 2010; Matuskey et al. 2013; Moeller et al. 2014a ) and subcortical regions Moeller et al. 2012a) . Moreover, CUD is classically associated with multiple neurocognitive deficits, including in inhibitory control (Luijten et al. 2014; Moeller et al. 2016) , which is a function indexed by the current drug-word and Stroop tasks. Secondarily, we examined (b) ADHD symptoms, as MPH modified neural responses during executive function to a greater extent in these individuals than healthy controls (Rubia et al. 2011a, b) , and (c) working memory capacity, as MPH has been shown to modulate task performance based on an individual's baseline ability (Mehta et al. 2000; van der Schaaf et al. 2013 ).
Methods Participants
Twenty-two CUD (20 males) and 21 healthy controls (20 males), recruited through advertisements in local newspapers and by word of mouth, participated in this research; all provided written informed consent in accordance with the Stony Brook University Institutional Review Board. All participants were medically healthy and not currently taking any medications. Based on a comprehensive diagnostic interview (Supplement), CUD was classified as either meeting diagnostic criteria for current cocaine dependence (N = 21) or abuse (N = 1) (see Table 1 for cocaine-related clinical information and the Supplement for additional clinical information, including CUD comorbidities). Exclusion criteria were as follows: (a) history of head trauma or loss of consciousness (>30 min) or other neurological disease of central origin (including seizures); (b) abnormal vital signs at time of screening; (c) history of major medical conditions, encompassing cardiovascular (high blood pressure, cardiac arrhythmias apart from sinus bradycardia, or an abnormal electrocardiography at screening), endocrinological (including metabolic), oncological, or autoimmune diseases; (d) history of major psychiatric disorder (other than substance abuse or dependence for CUD; healthy controls needed to be free of all psychiatric diagnoses, with the exception of nicotine dependence); (e) pregnancy (based on a urine test); (f) contraindications to MRI; (g) history of glaucoma; and (h) except for cocaine in CUD, positive urine screens for psychoactive drugs or their metabolites.
MPH administration
Participants were randomized to receive 20 mg oral MPH or placebo (lactose) on two study days, separated by approximately 1 to 2 weeks (CUD 9.2 ± 4.3 days; control 12.9 ± 11.6 days; p > 0.1). Oral MPH or placebo was given 60 min prior to testing, within the window of peak effects (60-120 min), first single blind (N = 31) and then transitioned to double blind (N = 12) (see Supplement for additional detail). MPH plasma concentrations were collected via venous blood draws before MPH, and at 45 and 120 min post-MPH, and were analyzed using capillary gas chromatography-mass spectroscopy (Srinivas et al. 1991) .
Study procedures
We aggregated and re-analyzed data from several of our previously published studies (Goldstein et al. 2010; Konova et al. 2013 Konova et al. , 2015 Moeller et al. 2012a Moeller et al. , 2014a . Task procedures encompassed a salient drug-word task, a color-word Stroop task, and a resting-state scan, all described below and completed in this fixed order. Forty participants (21 CUD, 19 controls) completed the drug-word task, 37 (20 CUD, 17 controls) completed the color-word Stroop task, and 33 (18 CUD, 15 controls) completed resting-state scans (16 CUD and 11 controls completed all three study procedures). Reasons for non-completion were generally incidental (e.g., time constraints), and completers of all three procedures were demographically and clinically similar to non-completers; the only (non-Bonferroni corrected) differences in Table 1 variables were in non-verbal IQ (higher in non-completers; p = 0.040) and pre-MPH cocaine craving (higher in completers on the MPH day; p = 0.013).
Salient drug-word task
Participants were instructed to press for the ink color of drug words or neutral words while ignoring the emotional salience of the drug words (e.g., Goldstein et al. 2009; Konova et al. 2012 Konova et al. , 2016 Moeller et al. 2012b Moeller et al. , 2013 . In brief, the task consisted of six 3.4-min task repetitions (three drug and three neutral), each containing two blocks of 20 drug or neutral words, interleaved with a 20-s fixation window. Participants performed each word sequence under one of three counterbalanced monetary reward amounts (50¢, 25¢, or 0¢), gained for correct performance for up to $75 of real money; participants could not lose money on the task. Each trial consisted of a 500-ms fixation, a 2000-ms word presentation (for word reading), a 500-ms response window, and a 500-ms feedback displaying the amount of money earned for a correct response or an BX^for an incorrect response. Word color order was pseudorandomized across all task runs.
Color-word Stroop task
Participants performed three runs of this event-related task, with instructions to press for the ink color of color-words (Wechsler 1999) t = 0.5 9.7 ± 2.9 10.1 ± 3.5
Depression: Beck Depression Inventory II (Beck et al. 1996 ) Z = −3.7*** 7.1 ± 5.3 1.9 ± 3.6
Socioeconomic status: Hollingshead Index t = 0.1 37.6 ± 9.0 37.2 ± 11.0 CAARS total score t = 1.4 9.3 ± 5.4 7.2 ± 7.4
Digit span (backwards) t = 1.3 4.5 ± 1.3 5.1 ± 1.7 Methylphenidate plasma levels t = 1.7 3.6 ± 2.0 2.7 ± 1.5 (red, blue, yellow, green) printed in their congruent (e.g., Bblue^in blue ink; 94 % of trials) or incongruent (e.g., blue in red ink; 6 % of trials) fonts (Leung et al. 2000; Moeller et al. 2012a Moeller et al. , 2014a Moeller et al. , b, 2015 . Because of our implicit task baseline of correct events (see fMRI analysis below), the task did not contain a jittered intertrial interval. No word or color of an incongruent stimulus mirrored the preceding congruent color-word; otherwise, stimuli were presented randomly. Each word was presented for 1300 ms (intertrial interval = 350 ms). Remuneration for task completion was fixed at $25.
Resting-state scan
Participants were instructed to keep their eyes open, lie as still as possible, and remain awake. Resting scan time was approximately 10 min in duration. This resting scan allowed us to determine global functional connectivity density, which is a data-driven connectivity-based approach that provides a metric of the total number of functional connections to a given region as previously described .
Individual difference variables

Diagnosis (CUD versus control)
Diagnosis constituted the individual difference variable of primary interest in this study, given the current addicted sample, with attendant dopaminergic compromises (Goldstein and Volkow 2011) , and given prior work by us and others indicating that MPH normalized behavior and brain function in this psychopathology (Goldstein et al. 2010; Konova et al. 2013; Li et al. 2010; Matuskey et al. 2013; Moeller et al. 2012a Moeller et al. , 2014a .
Symptoms of ADHD
Because the majority of the literature on MPH comes from ADHD, we examined participant responses on the Conners' Adult ADHD Rating Scale (CAARS) (Conners et al. 1999) . The CAARS, which was completed without MPH on board and outside of fMRI, provides selfassessment of severity of ADHD symptoms on a fourpoint scale (0 = not at all to 3 = very much).
Working memory
Digit span (backwards) (Wechsler 1997) , which measures attentional capacity and verbal working memory, was assessed as part of a comprehensive neuropsychological battery described elsewhere ). Similarly to CAARS, participants completed this measure without MPH on board and outside of fMRI, and thus, this measure reflects a general, dopaminergically relevant individual difference in working memory capacity. The contributions of dopamine to working memory are well characterized (D'Esposito and Postle 2015). Of relevance for the current study, digit span (backwards) is sensitive to dopamine neurotransmission, evidenced by a study in Parkinson's patients where performance on this measure was rescued by dopamine-enhancing medications (Cools et al. 2010) .
Data analysis
Data analysis proceeded in four phases. First, we defined and extracted average values of the fMRI bloodoxygenation-level-dependent (BOLD) signals in ten select ROIs for each of the three fMRI procedures, which were subsequently converted to z-scores to standardize measurements across procedures. Second, we averaged each participant's z-scored MPH minus placebo response across the three fMRI procedures in these ten brain regions. Third, we tested for associations between these averaged MPHs relative to placebo (MPH > placebo) signals and the dopamine-relevant individual difference variables. Fourth, we conducted supplementary analyses to help buttress interpretations for any significant differences revealed as part of the third phase. These four phases are described in further detail below (and in the Supplement).
Identification of brain regions potentially targeted by MPH
A priori unbiased, anatomical ROIs, created in PickAtlas, were defined in key brain regions relevant to dopaminergic neurotransmission that support a range of cognitive and emotional functions and that were engaged by MPH in our prior pharmacological fMRI studies using these same fMRI tasks, contrasts, and procedures (Goldstein et al. 2010; Konova et al. 2013 Konova et al. , 2015 Moeller et al. 2012a Moeller et al. , 2014a ; importantly, however, the current ROIs were independent from these prior studies' peak activations. . Acquisition and pre-processing procedures can be found in our prior reports (Goldstein et al. 2010; Konova et al. 2013 Konova et al. , 2015 Moeller et al. 2012a Moeller et al. , 2014a and are also provided in the Supplement for further reference.
To calculate individual BOLD-fMRI maps for the drugword monetary reward task, which has a blocked design comprising 128 time points, we used a box-car design convolved with a canonical hemodynamic response function and high-pass filter (cutoff frequency 1/520 s). Contrast maps reflecting the average percent signal change from the fixation baseline across all task conditions (0¢, 25¢, and 50¢ blocks, for both drug and neutral word blocks) were calculated for each participant. We analyzed this combined contrast to ensure maximum sample size for our analyses and because our previous results showed that the effects of MPH on this task generally did not vary by money or word conditions (Goldstein et al. 2010) . Indeed, in the current study, a 2 (medication: MPH, placebo) × 3 (money 0¢, 25¢, 50¢) × 2 (word: drug, neutral) × 2 (group: CUD, control) ANOVA on the behavioral data revealed no main effects or interactions with medication condition (all p > 0.108).
To calculate individual BOLD-fMRI maps for the colorword Stroop task, which has an event-related design comprising 207 time points, we used a general linear model with six motion regressors (three translation and three rotation) convolved with a canonical hemodynamic response function and a high-pass (cutoff frequency 1/90 s) filter. We computed a design matrix that specifically modeled all error events-given that our prior results with this task showed MPH effects for (all) error processing but not Stroop conflict processing (Moeller et al. 2012a (Moeller et al. , 2014a . This design matrix included one regressor collapsed across both error trials (Congruent Incorrect and Incongruent Incorrect), leaving both correct trials (Congruent Correct and Incongruent Correct) to serve as the active, implicit baseline, and was defined as (Incongruent Error + Congruent Error) − (Incongruent Correct + Congruent Correct). The number of errors on each study day and by study condition was as follows: 24.5 ± 17.4 for MPH congruent trials, 12.2 ± 8.1 for MPH incongruent trials, 42.6 ± 35.3 for placebo congruent trials, and 14.0 ± 8.5 for placebo incongruent trials. A 2 (medication: MPH, placebo) × 2 (condition: congruent, incongruent) × 2 (group: CUD, control) ANOVA on task errors revealed no effects of group but did reveal that all Connectivity analysis was based on our prior work (Tomasi and Volkow 2011), used to identify functional hubs in the human brain as determined by the density, or estimated number, of functional connections for a given brain region. Voxels with signal to noise as a function of time <50 were first eliminated to minimize unwanted effects from susceptibilityrelated signal-loss artifacts. The remaining preprocessed data then underwent global functional connectivity density mapping, where we computed the total number of functional connections of every voxel in the brain. The Pearson correlation was used to assess the strength of the functional connectivity of each voxel with each other voxel, and a correlation threshold of 0.6 was used to compute the binary undirected connectivity coefficient, a ij . This correlation threshold ensures significant correlations between time-varying signal fluctuations at p < 0.001 (family-wise error). The global functional connectivity density at every voxel was calculated from the N × (N − 1) / 2 binary matrices (N = 57,713 voxels) as k i = ∑a ij , using a C-algorithm and parallel computing .
Statistical analyses
Associations with individual difference variables We computed ten generalized linear models (GZLMs) with robust estimation, to account for violations of normality in some of the variables. The outcome variable in each model was the extracted MPH > placebo fMRI signal, averaged across all three fMRI procedures, in each brain ROI. Because activation in each brain region was averaged across the three procedures, participants were still included in the analyses even if they were missing data from a given procedure(s) (see Table 2 for sample sizes of each analysis); this more liberal inclusion was instituted to maximize sample size in this feasibility study. The predictor variables in these models were specified as either factors (diagnosis: CUD, control) or continuous covariates (CAARS and digit span). We also included a fourth (continuous) covariate in these models (MPH plasma level) because MPH permeability, which can be indexed by plasma levels, may also modulate MPH-related brain response (Muller et al. 2005) . To minimize type I error, we adopted a highly conservative p < 0.001 significance level for these analyses.
Supplementary analyses Additional analyses were conducted to help interpret and provide functional relevance to our main analyses above. First, in cases where a significant effect was observed across the three fMRI procedures, we conducted analyses separately for each fMRI procedure to examine whether a particular procedure(s) drove the aggregated effect (i.e., to explain the source of the effect in the averaged variables). Second, in cases where diagnosis (i.e., CUD, control) was the modulating variable, we examined associations with frequency of recent cocaine use (days per week, last 30 days) ( Table 1 ). Additional analyses, described in the Supplement, examined the respective influences of non-completion of all three fMRI tasks, laterality (among the already significant regions), and covariates that differed between the groups (age, depression, cigarette smoking history, and history of substance use comorbidities) and examined associations of brain data with task data. In all supplementary analyses, effects were considered significant at the more traditional p < 0.05 threshold (i.e., since the primary brain effect needed to have been already observed at the conservative p < 0.001 threshold). Table 2 displays all GZLM coefficients and significance levels. Diagnosis membership (CUD versus control) was associated with averaged MPH > placebo response in the DLPFC; that is, CUD had reduced aggregate DLPFC response to MPH, whereas controls had increased aggregate DLPFC response to MPH (Fig. 2a) [also note a similar, albeit non-significant, direction of correlations in most other cortical regions (Table 2) ]. This DLPFC effect was independent of the amount of MPH in plasma, a variable that correlated with midbrain MPH > placebo response (the higher the plasma MPH, the greater the MPH > placebo response in midbrain) ( Table 2) . No other associations reached significance at the conservative p < 0.001 threshold.
Results
MPH effects on aggregated fMRI response
Supplementary analyses
When examining each fMRI procedure separately, the CUD participants had reduced DLPFC response as measured with the drug-word task (p = 0.006) and the color-word Stroop task (p = 0.005); a similar, albeit not significant, pattern was observed for resting-state functional connectivity (p = 0.408) (Fig. 2a) . These supplemental analyses suggest that MPH exerts a common signature in the DLPFC that is modulated by diagnosis, although this signature may be more prominent during the performance of inhibitory control tasks than during rest.
Given the association between diagnosis and DLPFC, we tested, within CUD only, whether the amount of DLPFC modulation (combined measure across the three procedures) by MPH was associated with current frequency of cocaine use (last 30 days). Results showed that DLPFC modulation by MPH was negatively associated with recent drug use (i.e., the more MPH decreased fMRI response in the DLPFC, the greater the current drug use) (Fig. 2b) . This correlation was also significant for each of the three fMRI procedures when considered separately (drug-word task: p = 0.032; color-word Stroop task: p = 0.035; resting-state connectivity: p = 0.021).
Thus, MPH may have exerted the greatest benefit in individuals who needed it most (i.e., CUD with the most frequent current drug use).
Additional analyses, described more comprehensively in the Supplement, indicated that these DLPFC results were not attributable to the following: demographic or clinical (including drug use comorbidities) differences between groups, noncompletion of all three fMRI procedures, or laterality effects. Moreover, there were interesting, though non-significant, trends toward decreased MPH > placebo DLPFC correlating with better MPH > placebo task performance. Numbers represent unstandardized regression coefficients (b), with associated standard errors (SE); for diagnosis, healthy controls are the reference group [i.e., a negative slope indicates decreased methylphenidate (versus placebo) response in cocaine participants]; for the continuous variables, negative slopes indicate that methylphenidate (versus placebo) response is associated with less ADHD symptomatology, less working memory, and less methylphenidate plasma levels, respectively CUD individuals with cocaine use disorder, HC healthy control, ACC anterior cingulate cortex, DLPFC dorsolateral prefrontal cortex, OFC orbitofrontal cortex *p < 0.001, +p < 0.05 (possible interesting effects to follow up on in future studies) Fig. 2 Associations with individual characteristics relevant to dopaminergic signaling. a Cocaine use disorder is associated with decreased response to methylphenidate (MPH) versus placebo in the dorsolateral prefrontal cortex (DLPFC) (Brodmann areas 9 and 46) across all three procedures [and specifically in the drug-word (DW) task and the color-word (CW) Stroop task), but less so for resting-state functional connectivity (RSFC) density] (asterisks indicate a significant difference between groups) and b the greater the decrease in DLPFC MPH > placebo signal across the three fMRI procedures, the more frequently cocaine was used in the last 30 days
Regions of interest (participant
Discussion
In this study, we aggregated individuals' response to MPH in ten cortical and subcortical brain regions across three different fMRI procedures, encompassing a salient drug-word task, a color-word Stroop task, and hub-based resting-state functional connectivity. We then correlated this combined MPH (relative to placebo) response with dopaminergically relevant individual difference variables related to clinical phenotypes. To our knowledge, this is the first study to examine the individual characteristics, including a substance use disorder, that associate with multimodal fMRI responsiveness to MPH. Across the three fMRI procedures, compared with healthy controls, individuals with CUD showed a reduction in DLPFC activity/connectivity with MPH. Modulation of the DLPFC by MPH may be associated with the modulation of executive functions needed to perform the current inhibitory control tasks, potentially including non-emotional conflict resolution and the implementation of cognitive control (Egner et al. 2008; Kerns et al. 2004; Luijten et al. 2014) , and/or working memory (Brunoni and Vanderhasselt 2014; Owen et al. 2005) (although note that working memory itself was not associated with MPH response in this region). Additional studies are needed to evaluate MPH effects on DLPFC connectivity, which, in the current study, showed a similar, albeit non-significant, pattern of effects as the task data. Indeed, little work has examined the effects of MPH on DLPFC connectivity during resting state, though one study in healthy controls reported that thalamic-DLPFC connectivity was reduced with MPH (Farr et al. 2014) , which is the pattern that we observed here for CUD. Importantly, the combined DLPFC modulation by MPH (i.e., tasks and resting state) was further correlated with the frequency of recent cocaine use. Given this correlation, it is reasonable to attribute the DLPFC effect to active cocaine use, rather than simply to CUD diagnosis (that may contain attendant potential confounds, such as issues with incomplete group matching and/or comorbid drug use including cigarette smoking). Although the neurochemical mechanism of the current effects remains to be determined, one possibility is that, in the individuals for whom dopamine signaling is perturbed (i.e., CUD) (Volkow et al. 2014 )-and perhaps especially in CUD with the most frequent drug use-MPH produced a pattern of more efficient brain responses (Swanson et al. 2011) . Although it was somewhat surprising that similar effects did not emerge for CAARS (ADHD index), null effects could be attributable to the very conservative significance threshold and by the current sample that was not selected a priori to exhibit ADHD symptoms.
Our results are consistent with other studies finding that MPH reduces neural activity/connectivity across multiple psychopathologies. In ADHD, MPH reduced prefrontal cortex fMRI response and regional cerebral blood flow (Liddle et al. 2011; Peterson et al. 2009; Schweitzer et al. 2003 Schweitzer et al. , 2004 , and improvements in ADHD symptoms following a therapeutic course of MPH were associated with reduced activity in several prefrontal regions including the left ACC/supplementary motor area (Schulz et al. 2012) . A meta-analysis of fMRI studies in ADHD showed that MPH decreased activation during response inhibition and error processing in the dorsal ACC/supplementary motor area (although other regions, such as the inferior frontal gyrus and insula, showed an opposite direction of effects) (Rubia et al. 2014) . In traumatic brain injury, MPH reduced global gray matter cerebral blood flow (Kim et al. 2012 ) and decreased fMRI activation (in ACC, thalamus, and other regions) during performance of a working memory (N-back) task (Newsome et al. 2009 ). In methamphetamine-addicted individuals, MPH (relative to placebo) decreased activation in parietal and occipital regions during color-word Stroop incongruent trials (Jan et al. 2014) . In CUD, MPH reduced an abnormally high (i.e., normalized, such that differences from healthy controls were attenuated) functional connectivity in an important striatal habit formation pathway . Of greater importance for the current study, MPH also decreased BOLD-fMRI response in the DLPFC during the color-word Stroop (i.e., such that CUD resembled controls during placebo) (Moeller et al. 2014a )-although here, we showed that this response was driven not only by the color-word Stroop task, but also by the drug-word task and by a similar pattern also during rest. In other research, reduced DLPFC fMRI response predicted better clinical outcome (treatment retention) in CUD (Brewer et al. 2008) .
The primary limitation of this study is the sample composition. Given that the primary consideration throughout all analyses of this feasibility study was to maximize sample size, we included participants with incomplete data; consequently, we did not conduct stringent group matching (e.g., on age or comorbid drug use including cigarette smoking history) nor did we precisely interrogate task condition effects. Prioritizing these other considerations would have compromised power, either by reducing the number of participants and/or by reducing the number of task trials available for analysis. Thus, although covariation analyses indicated that these respective factors did not drive our findings (BResults^section and Supplement), future studies are needed with larger samples. Larger samples will enable the following: analyses to be restricted to individuals with complete data, better group matching, study conditions to be appropriately isolated (e.g., money versus word effects in the drug-word task; congruency versus error effects in the color-word Stroop task) and laterality to be examined in greater depth. For the latter, however, even for regions showing laterality effects during Stroop-like tasks, the difference between the functions subserved by left and right hemispheres appears nuanced. For example, the left DLPFC may be particularly active during conflict (i.e., to adjust the previous task strategy), whereas the right DLPFC may be particularly active after conflict (i.e., to maintain the new task strategy) (Vanderhasselt et al. 2009 ); in this feasibility study, we could not conduct such fine-grained analyses, and indeed, we did not find evidence of laterality effects in this DLPFC region (Supplement). A second limitation is that conclusions are constrained by the fMRI procedures/contrasts and brain regions that we selected. Different tasks and/or fMRI contrasts may have yielded different results, potentially helping to explain an opposite (increased) pattern of MPH effects in other studies [e.g., ADHD (Bush et al. 2008; Cubillo et al. 2014a, b; Rubia et al. 2014; Wong and Stevens 2012) ; traumatic brain injury (Kim et al. 2009 ); CUD (Camchong et al. 2011; Goldstein et al. 2010) ]. Thus, future studies aiming to integrate brain function across multiple experimental procedures may wish to incorporate tasks that have similar baseline conditions and similar structural designs (e.g., all event-related). For the latter, however, it is important to note that studies comparing block designs versus event-related designs of the same experimental paradigm, whether emotionally neutral or emotionally salient, have largely reported highly overlapping fMRI activations (Buhler et al. 2008; Chee et al. 2003) ; accordingly, it is unlikely that the use of both blocked and event-related designs substantially modified any of our interpretations. Nevertheless, interpretative issues with fMRI tasks underscore the importance in the current study of including functional connectivity density, which is not constrained by task idiosyncrasies. A final limitation is that MPH also blocks the norepinephrine transporter (Hannestad et al. 2010) . Even so, the mechanism of optimization could still be dopaminergic because norepinephrine transporters also have affinity for dopamine (Hannestad et al. 2010) , especially in prefrontal regions (where norepinephrine transporters outnumber dopamine transporters).
In summary, individual differences related to dopamine signaling (e.g., a CUD) predict MPH response across multiple, disparate fMRI procedures. Our data favor the interpretation that a reduced (potentially more efficient) DLPFC response to MPH versus placebo characterizes individuals with CUD across a range of contexts. Furthermore, this effect may be accentuated in those using cocaine at a higher frequency-a possibility not previously examined in clinical trials of MPH in substance users that may have contributed to mixed findings (Gawin et al. 1985; Grabowski et al. 1997 ). More broadly, combining multiple fMRI measures inclusive of cognitive tasks and resting state can provide new insights into the mechanisms underlying the effects of dopamine agonists on brain function in health and disease.
